Murine monoclonal antibodies specific for Treponema denticola serovar C were produced and characterized in this study. An immunoassay was then developed by using these monoclonal antibodies, and the T. denticola serovar C antigen content of subgingival plaque was quantitated for samples taken from patients with periodontitis and healthy volunteers. The human subgingival plaque samples were grouped by severity of disease and pocket depth measurements at the collection site. The T. denticola serovar C content per milligram of subgingival plaque from deep pockets (>6 mm) of patients with severe periodontitis was found to be twice that of samples collected from deep pockets (4 to 6 mm) of patients with moderate periodontitis or samples collected from healthy subjects (pocket depth, <4 mm).
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Several studies have shown that oral spirochetes are associated with severe periodontitis in adults (1, 3-5, 7). Treponema denticola is a specific spirochete component of human subgingival plaque that has been shown to be elevated in patients with severe periodontitis (9) . T. denticola and certain other oral spirochetes were similarly found to be associated with moderate periodontitis in humans (6) . The immunoassay approach with monoclonal antibodies (MAbs) to oral microbial antigens has greatly facilitated the detection and quantitation of T. denticola in human clinical studies (9) . The immunoassay approach is based upon the use of highly specific MAbs to oral microbial antigens. In an earlier report (10), a MAb that was able to detect 8 of 15 T. denticola isolates was described. In the present study, we produced and characterized MAbs to isolates (serovar C) which did not react with the previously described MAbs. A clinical immunoassay for the detection and quantitation of T. denticola serovar C antigen in human subgingival plaque samples from healthy and periodontally diseased sites is also de- Tables 1 and 2 ). Antibody isotyping was performed by immunodiffusion and ELISA as described previously (10) .
Immunoelectron microscopy. The location of the antigenic target of the MAb was determined by transmission electron microscopy as described previously (10) . In this study. T. denticola ATCC 33520 was fixed, washed, and treated with uninoculated tissue culture medium (negative control) or with MAb (culture supernatant from hybridoma TDIII, IIIBB2).
Antigen detection in clinical samples. Subgingival plaque samples were collected from 29 volunteers at the periodontics clinic of Northwestern University Dental School. Some specific parameters of this population are presented in Table  3 . The subjects were divided into three groups, as described previously (9) , according to the severity of their periodontal disease and pocket depth at the sample site. Periodontally healthy subjects exhibited probing depths of <4 mm with little or no gingival inflammation and no radiographic evidence of alveolar bone loss. The remaining two groups were subjects with case type III or IV periodontitis (8 Tables   1 and 2 . The ELISA results indicate that the MAbs were specific for T. denticola serovar C, as defined by Cheng et al.
(2). Nonspecific reactions with 61 additional microbial antigens were not observed. The MAbs from this fusion did not react with T. denticola isolates that were reactive with a previously developed MAb, TDII,IAAII (10) . The MAb from TDII,IAAII was created by using T. denticola ATCC 33521 as the immunogen.
The cellular location of the epitope target of MAb location of the gold spherical label was associated with the outer sheath portion of the spirochete cell. The negative control did not label the cells. The sensitivity and relative linearity of the biotin-streptavidin-urease ELISA are shown in Fig. 2 . A similar standard curve from 0 to 20 ,ug of T. denticola whole-cell antigens was created in each assay plate containing clinical subgingival plaque samples. The assay was useful over this range, and the lower limit of sensitivity was in the 1-to 2-,ug range. Negative control wells incubated with uninoculated medium served as the absorbance blank.
Clinical parameters and microgram quantities of T. denticola serovar C antigen equivalents found per milligram of subgingival plaque are given in Table 3 . A total of 17 males and 12 females (age range, 32 to 72 years) were included in this study. The mean microgram content of T. denticola serovar C per milligram of plaque increased with pocket depth, although the means for the three groups were not significantly different (P = 0.27 by analysis of variance). The group with the deepest pocket depth (>6 mm, indicating severe disease) had almost twice the serovar C content of the groups with pocket depths of <4 mm (healthy) and 4 to 6 mm (moderate disease). From 71 to 86% of all sites were positive for some level of serovar C antigen.
DISCUSSION
In this report we described the first hybridoma cell line which secretes a MAb specific for serovar C isolates of T. denticola (2). The MAb secreted by clone TDIII,IIIBB2 never cross-reacted with microbial antigens other than T. denticola serovar C. A negative stain following immunogold labeling showed that the MAb reacted with the outer sheath portion of the spirochete cell surface. The murine MAb was shown to be an IgG2A heavy-chain, kappa-light-chain isotype. This report provides the first quantitative estimate of T. denticola serovar C antigen present in human clinical samples. The TDIII,IIIBB2 MAb was used in an ELISA to measure the T. denticola serovar C content of subgingival plaque samples obtained from volunteer adult patients with periodontitis at a university clinic and from healthy controls. A biotin-streptavidin-enhanced ELISA was performed in which urease was used as the enzyme label. Similar to the result of a previous study (9) , the mean T. denticola content was found to increase as pocket depth and severity of disease increased. The group with the deepest pocket depth (>6 mm) was found to have almost twice the T. denticola (serovar C) content of the healthy control group (3.6 pg/mg) and the group with moderate disease (3.9 ,ug/mg). The serovar C content of the groups of subjects examined in this study was only about 5% of the level detected in three similar groups in a previous study with MAb TDII,IAAII (9). This observation was consistent for each of the three groups. In the previous study (9), the T. denticola content was 139.5 ,uig/mg for the group with deep pockets (>6 mm), 68.2 ,ug/mg for the group with moderate pocket depths (4 to 6 mm), and 74.3 ,ug/mg for the healthy controls. Although the T. denticola serovar C content was elevated in the deep pockets of patients with severe periodontitis, our results suggest that serovar C may not be one of the major serotypes of T. denticola associated with severe periodontitis in humans. It is possible that some serotypes of T. denticola are more rare in humans or that certain serotypes may be more related to periodontitis than others, as judged by their greater population levels.
